Analyst Price Target is $4.26
▲ +102.86% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Standard BioTools in the last 3 months. The average price target is $4.26, with a high forecast of $7.00 and a low forecast of $2.30. The average price target represents a 102.86% upside from the last price of $2.10.
Current Consensus is
The current consensus among 5 contributing investment analysts is to hold stock in Standard BioTools. This Hold consensus rating has held steady for over two years.
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.